Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Essen Biotech
OncoNano Medicine, Inc.
Mayo Clinic
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Case Comprehensive Cancer Center
City of Hope Medical Center
City of Hope Medical Center
Bio-Path Holdings, Inc.
City of Hope Medical Center
Celldex Therapeutics
Stanford University
Stanford University
University of Nebraska
University of Nebraska
NovalGen Ltd.
Eastern Cooperative Oncology Group
Seagen Inc.
Atara Biotherapeutics
Columbia University
Thomas Jefferson University
Roswell Park Cancer Institute
Opna Bio LLC
Alexion Pharmaceuticals, Inc.
Northwestern University
Roswell Park Cancer Institute
AbbVie
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
Mayo Clinic
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Wisconsin, Madison
Mayo Clinic
Roswell Park Cancer Institute